---
title: Reduce movement problems with supplement
nct_id: NCT07064005
phase: PHASE1
status: RECRUITING
sponsor: Pravat Mandal
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07064005"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07064005"
last_fetched: "2026-05-10T14:05:58.445Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce movement problems with supplement

**Goal (in five words):** Reduce movement problems with supplement

**Official Title:** Brain Glutathione (GSH) Enrichment Through Gamma-glutamylcysteine (GGC) Supplementation in Early Parkinson's Disease Patients for Reduction of Extrapyramidal Motor Disturbances and Halting Cognition Decline: A Pilot Trial

**Trial ID:** [NCT07064005](https://clinicaltrials.gov/study/NCT07064005)

## Key Facts

- **Phase:** PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Pravat Mandal
- **Target Enrollment:** 12 participants
- **Start Date:** 2026-03-23
- **Completion Date:** 2027-09
- **Conditions:** Parkinsons Disease (PD)
- **Interventions:** Gamma- glutamylcysteine
- **Intervention Types:** DRUG

## Summary For Families

The goal is to see whether boosting brain glutathione can reduce Parkinson's extrapyramidal movement problems and help prevent early thinking decline. In a Phase 1 pilot, participants take gamma-glutamylcysteine, the direct building block the body uses to make glutathione, with the idea that higher antioxidant levels in the brain will protect dopamine neurons from oxidative damage; it is intended as an add-on not a replacement for levodopa, and no specific interactions with levodopa are expected. The trial will enroll 12 people aged 50 to 80 with confirmed Parkinson's and normal cognition on the MoCA (score ≥ 26), who can read and write English. People with metal implants or claustrophobia, dementia, active psychosis, recent serious liver or kidney disease, current antioxidant supplements, recent head injury, cancer, or substance abuse are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Confirmed Parkinson's Disease diagnosis.
* Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
* Age (50 to 80 years of age).
* Ability to read and write in English.

Exclusion Criteria:

* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
* Subjects with claustrophobia.
* Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
* Subjects with a history of cancer.
* Subjects with active psychosis or delirium.
* Subjects with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.
* Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl).
* Subjects with previous traumatic head injury.
```

## Locations (1)

- UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States _(40.4406, -79.9959)_
  - Pravat K Mandal, PhD — (CONTACT) — 4126999561 — mandalpk@pitt.edu

## Central Contacts

- Pravat K MANDAL, PHD — (CONTACT) — 4126999561 — mandalpk@pitt.edu
- Nazia Pillar, M.S — (CONTACT) — 878-670-3123 — naa430@pitt.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07064005*  
*HTML version: https://parkinsonspathways.com/trial/NCT07064005*  
*Source data: https://clinicaltrials.gov/study/NCT07064005*